Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine is a local anesthetic of the amide type and a class Ib antiarrhythmic agent. It is widely used to provide local or regional anesthesia by nerve blockade at various sites in the body and for the treatment of ventricular arrhythmias. Lidocaine works primarily by blocking voltage-gated sodium channels (especially Sodium channel protein type 1 subunit alpha) on neuronal cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. This action results in reversible loss of sensation in targeted tissues. In cardiac tissue, lidocaine raises the depolarization threshold by blocking sodium channels during their open and inactive states, reducing abnormal automaticity and suppressing arrhythmias[1][5][6][8]. Additionally, lidocaine exhibits anti-inflammatory effects through inhibition of pro-inflammatory cytokine release[6]. It was first introduced for clinical use in the late 1940s.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine.